Literature DB >> 18985396

Endemic linezolid-resistant Staphylococcus epidermidis in a critical care unit.

M Treviño1, L Martínez-Lamas, P A Romero-Jung, J M Giráldez, J Alvarez-Escudero, B J Regueiro.   

Abstract

The aim of this article was to report the emergence of patient infections with linezolid-resistant Staphylococcus epidermidis (LRSE) in a tertiary university hospital. Our objectives were to determine the molecular mechanism of the resistance, set up the genetic relationship among isolates, and analyze the relations between linezolid usage, period of treatment, and emergence of resistance in the hospital. The emergence of infection with linezolid-resistant S. epidermidis affecting 20 patients in a tertiary university hospital was investigated using repetitive sequence-based PCR (rep-PCR, DiversiLab System; BioMérieux, Inc., France). The presence of the G2576T mutation of 23S rRNA was screened by pyrosequencing. We determined the pattern of linezolid usage in the hospital as a whole and in the critical care unit that was most affected. G2576T mutation of 23S rRNA was detected in all linezolid-resistant S. epidermidis studied. Of these, 90% were genetically related and had been recovered from patients admitted to the same critical care unit. There had been an increase in linezolid usage in the hospital and in the critical care unit in the 2 years prior to the emergence of resistant strains. More strict control measures in hand washing and linezolid prescription were subsequently established, but no reduction in LRSE rates have yet been observed. Linezolid-resistant S. epidermidis emerged at our hospital, probably from a single strain originating in the critical care unit. The most likely explanation is that person-to-person spread of linezolid-resistant S. epidermidis led to skin colonization and, after linezolid treatment, this resistant staphylococci became the dominant cutaneous flora causing infection in some critical patients. In order to preserve the usefulness of this antibiotic as a therapeutic agent and to avoid a situation similar to methicillin-resistant Staphylococcus aureus, judicious use of antibiotics is essential.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985396     DOI: 10.1007/s10096-008-0657-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Linezolid resistance in clinical isolates of Staphylococcus aureus.

Authors:  Peter Wilson; J A Andrews; R Charlesworth; R Walesby; M Singer; D J Farrell; M Robbins
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

2.  Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.

Authors:  S H Marshall; C J Donskey; R Hutton-Thomas; R A Salata; L B Rice
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

3.  Microbial DNA typing by automated repetitive-sequence-based PCR.

Authors:  Mimi Healy; Joe Huong; Traci Bittner; Maricel Lising; Stacie Frye; Sabeen Raza; Robert Schrock; Janet Manry; Alex Renwick; Robert Nieto; Charles Woods; James Versalovic; James R Lupski
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Molecular characterization of hand flora and environmental isolates in a community setting.

Authors:  Preeti Pancholi; Mimi Healy; Tracy Bittner; Renee Webb; Fan Wu; Allison Aiello; Elaine Larson; Phyllis Della Latta
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Sequential linezolid-resistant Staphylococcus epidermidis isolates with G2576T mutation.

Authors:  Tao Hong; Xiangyang Li; Jie Wang; Cynthia Sloan; Cristina Cicogna
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

6.  Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Authors:  Ronald N Jones; James E Ross; Thomas R Fritsche; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2005-12-02       Impact factor: 5.790

7.  In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.

Authors:  Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  A semiquantitative culture method for identifying intravenous-catheter-related infection.

Authors:  D G Maki; C E Weise; H W Sarafin
Journal:  N Engl J Med       Date:  1977-06-09       Impact factor: 91.245

9.  An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit.

Authors:  Sinéad Kelly; Jonathan Collins; Maureen Maguire; Catriona Gowing; Michelle Flanagan; Maria Donnelly; Philip G Murphy
Journal:  J Antimicrob Chemother       Date:  2008-02-13       Impact factor: 5.790

10.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

View more
  8 in total

Review 1.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

2.  Clustering of clinical and environmental Escherichia coli O104 isolates using the DiversiLab™ repetitive sequence-based PCR system.

Authors:  N M Herbold; L M Clotilde; K M Anderson; J Kase; G L Hartman; S Himathongkham; A Lin; C R Lauzon
Journal:  Curr Microbiol       Date:  2014-12-02       Impact factor: 2.188

3.  Characterization of Staphylococcus caprae Clinical Isolates Involved in Human Bone and Joint Infections, Compared with Goat Mastitis Isolates.

Authors:  J d'Ersu; G G Aubin; P Mercier; P Nicollet; P Bémer; S Corvec
Journal:  J Clin Microbiol       Date:  2015-10-28       Impact factor: 5.948

4.  Polyphyletic emergence of linezolid-resistant staphylococci in the United States.

Authors:  Agnes Wong; Shilpa P Reddy; Davida S Smyth; Maria E Aguero-Rosenfeld; George Sakoulas; D Ashley Robinson
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

5.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

6.  Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France.

Authors:  Laurent Dortet; Philippe Glaser; Najiby Kassis-Chikhani; Delphine Girlich; Philippe Ichai; Marc Boudon; Didier Samuel; Elodie Creton; Dilek Imanci; Rémy Bonnin; Nicolas Fortineau; Thierry Naas
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

7.  Genomic and Phenotypic Analysis of Linezolid-Resistant Staphylococcus epidermidis in a Tertiary Hospital in Innsbruck, Austria.

Authors:  Silke Huber; Miriam A Knoll; Michael Berktold; Reinhard Würzner; Anita Brindlmayer; Viktoria Weber; Andreas E Posch; Katharina Mrazek; Sarah Lepuschitz; Michael Ante; Stephan Beisken; Dorothea Orth-Höller; Johannes Weinberger
Journal:  Microorganisms       Date:  2021-05-10

8.  Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012-2016).

Authors:  Matthaios Papadimitriou-Olivgeris; Fevronia Kolonitsiou; Vasileios Karamouzos; Katerina Tsilipounidaki; Alexandra Nikolopoulou; Fotini Fligou; Markos Marangos; Efthimia Petinaki; Iris Spiliopoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-02       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.